|
|
|
|
|
|
| (especial para SIIC © Derechos reservados) |
| Ignacio García Doval* Autor invitado por SIIC |
|
 Profundizar Referencias bibliográficas |
| Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 118:1416, 2005. Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 19:471-5, 2002. Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756-61, 2007. Ito M, Nakano T, Kamiya T, et al. Effects of tumor necrosis factor alpha on replication of varicella-zoster virus. Antiviral Res 15:183-92, 1991. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57:1431-8, 2007. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45:1370-5, 2006. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-44, 2009. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766-72, 2005. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-7, 2003. MedDRA Maintenance and Support Services Organization. http://www.meddramsso.org. Accessed 26 Mar 2010. Ministerio de Sanidad y Consumo. Encuesta Nacional de Salud 2003. http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/home.htm. Accessed 27 Oct 2008. Instituto Nacional de Estadística (INE). http://www.ine.es. Accessed 28 Nov 2008. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880-5, 2007. Carmona L, Hernández-García C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436-9, 2003. Spanish Society of Rheumatology. BIOBADASER: Spanish Registry for Adverse Events of Biological Therapies in Rheumatic Diseases. http://biobadaser.ser.es/biobadaser/eng/index.html. Accessed 26 Mar 2010. Descalzo MA, Biobadaser Scientific Committee (CC), Biobadaser Study Group (SG). Spanish registry for adverse events of biological therapies in rheumatic diseases (BIOBADASER): State Report on January 26th 2006. Reumatol Clin 3:4-20, 2007. Terris DD, Litaker DG, Koroukian SM. Health state information derived from secondary databases is affected by multiple sources of bias. J Clin Epidemiol 60:734-41, 2007. Calle JE, Saturno PJ, Parra P, et al. Quality of the information contained in the minimum basic data set: results from an evaluation in eight hospitals. Eur J Epidemiol 16:1073-80, 2000. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 10:571-81, 1996. Nilsson A, Ortqvist A. Severe varicella pneumonia in adults in Stockholm County 1980-1989. Scand J Infect Dis 28:121-3, 1996. De Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946-52, 2006. Torigo S, Ihara T, Kamiya H. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol Immunol 44:1027-31, 2000. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-4):1-40, 2007. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271-84, 2005. Peña-Rey I, Martínez de Aragón MV, Villaverde Hueso A, et al. Epidemiology of varicella in Spain pre- and post-vaccination periods. Rev Esp Salud Publica 83:711-24, 2009. |
|
Acerca del trabajo completo |
| AUMENTO DE LA GRAVEDAD, PERO NO CLARAMENTE DE LA FRECUENCIA, DE INFECCIONES POR VIRUS HERPES ZOSTER EN PACIENTES CON ANTI-TNF |
| Título original en castellano INCIDENCIA Y RIESGO DE HOSPITALIZACIÓN POR VARICELLA O HERPES ZOSTER EN PACIENTES CON ENFERMEDADES REUMÁTICAS TRATADAS CON ANTAGONISTAS DEL TNF |
| Autores Ignacio García Doval1, Beatriz Pérez-Zafrilla2, Miguel Ángel Descalzo3 |
| 1 Médico, Complexo Hospitalario de Pontevedra, Facultativo Especialista de Área 2 Farmaceútica 3 Estadístico |
| Acceso a la fuente original Annals of the Rheumatic Diseases |
| http://ard.bmjjournals.com/ |
Acceso al texto original completo (full text) |
Acceso al resumen/abstract original |
| El artículo se relaciona estrictamente con las especialidades de siicsalud | |
|
ua90911 |
Acerca de SIIC Estructura de SIIC
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina Tel: +54 11 4342 4901; Fax: +54 11 4331 3305 Casilla de Correo 2568, (C1000WAZ) Correo Central, Buenos Aires Copyright siicsalud© 1997-2013, Sociedad Iberoamericana de Información Científica (SIIC) ISSN siicsalud: 1667-9008 ua4711 Mensajes a SIIC |
